Answer
Yes, elacestrant (given as elacestrant dihydrochloride) inhibits oestradiol-dependent and independent growth of ERα-positive breast cancer cells, including models harbouring ESR1 gene mutations.
Sources for this answer
- Korserdu (elacestrant) 345mg film-coated tabletsMenarini Stemline UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 4Document updated
Sources checked